Total submissions: 45
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000114009 | SCV000321230 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2016-09-28 | reviewed by expert panel | curation | Class 1 not pathogenic based on frequency >1% in an outbred sampleset. Frequency 0.036 (Admixed American/Latino), 0.0215 (South Asian), derived from 1000 genomes (2013-05-02). |
Invitae | RCV000045643 | SCV000073656 | benign | Hereditary breast ovarian cancer syndrome | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000114009 | SCV000154050 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2014-01-02 | criteria provided, single submitter | literature only | |
Gene |
RCV000120367 | SCV000167416 | benign | not specified | 2013-10-02 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Ambry Genetics | RCV000128883 | SCV000172740 | benign | Hereditary cancer-predisposing syndrome | 2014-08-01 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Michigan Medical Genetics Laboratories, |
RCV000114009 | SCV000196019 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2014-11-03 | criteria provided, single submitter | clinical testing | |
Pathway Genomics | RCV000114009 | SCV000223768 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2014-10-30 | criteria provided, single submitter | clinical testing | |
Eurofins Ntd Llc |
RCV000120367 | SCV000227874 | benign | not specified | 2015-07-30 | criteria provided, single submitter | clinical testing | |
Vantari Genetics | RCV000128883 | SCV000267027 | benign | Hereditary cancer-predisposing syndrome | 2016-01-06 | criteria provided, single submitter | clinical testing | |
Genomic Diagnostic Laboratory, |
RCV000045643 | SCV000296861 | benign | Hereditary breast ovarian cancer syndrome | 2015-10-20 | criteria provided, single submitter | clinical testing | |
CHEO Genetics Diagnostic Laboratory, |
RCV000768611 | SCV000324842 | benign | Breast and/or ovarian cancer | 2016-01-04 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000114009 | SCV000383795 | likely benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2018-01-29 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to determine this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. |
Illumina Laboratory Services, |
RCV000322663 | SCV000383796 | likely benign | Fanconi anemia complementation group D1 | 2018-01-29 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases allowed determination this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000045643 | SCV000494370 | benign | Hereditary breast ovarian cancer syndrome | 2014-02-04 | criteria provided, single submitter | clinical testing | |
Center for Pediatric Genomic Medicine, |
RCV000034468 | SCV000510683 | benign | not provided | 2016-09-28 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000128883 | SCV000537387 | benign | Hereditary cancer-predisposing syndrome | 2014-12-30 | criteria provided, single submitter | clinical testing | |
Laboratory for Molecular Medicine, |
RCV000120367 | SCV000538465 | benign | not specified | 2016-03-28 | criteria provided, single submitter | clinical testing | Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: ExAC: 3.5% (402/11526) Latino chromosomes |
Baylor Genetics | RCV000476344 | SCV000541045 | benign | Familial cancer of breast | 2017-02-23 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000114009 | SCV000575751 | likely benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2015-12-07 | criteria provided, single submitter | clinical testing | |
Cancer Genetics and Genomics Laboratory, |
RCV000120367 | SCV000586986 | benign | not specified | 2017-04-18 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV000034468 | SCV000602773 | benign | not provided | 2023-11-27 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV000114009 | SCV000743355 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2014-10-09 | criteria provided, single submitter | clinical testing | |
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000114009 | SCV000744552 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2015-09-21 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV000120367 | SCV000805788 | benign | not specified | 2016-10-31 | criteria provided, single submitter | clinical testing | |
National Health Laboratory Service, |
RCV000045643 | SCV002025863 | benign | Hereditary breast ovarian cancer syndrome | 2021-11-16 | criteria provided, single submitter | clinical testing | |
Genetics Program, |
RCV000045643 | SCV002515159 | benign | Hereditary breast ovarian cancer syndrome | 2021-11-01 | criteria provided, single submitter | research | |
Sema4, |
RCV000128883 | SCV002531981 | benign | Hereditary cancer-predisposing syndrome | 2020-03-20 | criteria provided, single submitter | curation | |
Ce |
RCV000034468 | SCV002545115 | benign | not provided | 2024-07-01 | criteria provided, single submitter | clinical testing | BRCA2: PM5, BP4, BS1, BS2 |
Center for Genomic Medicine, |
RCV000120367 | SCV002551835 | benign | not specified | 2023-08-15 | criteria provided, single submitter | clinical testing | |
Genetics and Molecular Pathology, |
RCV000114009 | SCV002556904 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2022-05-25 | criteria provided, single submitter | clinical testing | The BRCA2 c.8851G>A variant is classified as Benign |
Laboratory of Molecular Epidemiology of Birth Defects, |
RCV003153321 | SCV003843720 | likely pathogenic | Ovarian cancer | 2022-01-01 | criteria provided, single submitter | clinical testing | |
KCCC/NGS Laboratory, |
RCV000114009 | SCV004016828 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2023-07-07 | criteria provided, single submitter | clinical testing | |
All of Us Research Program, |
RCV000114009 | SCV004846083 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2024-02-05 | criteria provided, single submitter | clinical testing | |
Biesecker Lab/Clinical Genomics Section, |
RCV000034468 | SCV000043234 | no known pathogenicity | not provided | 2012-07-13 | no assertion criteria provided | research | Converted during submission to Benign. |
ITMI | RCV000120367 | SCV000084519 | not provided | not specified | 2013-09-19 | no assertion provided | reference population | |
Breast Cancer Information Core |
RCV000114009 | SCV000147474 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2002-05-29 | no assertion criteria provided | clinical testing | |
Sharing Clinical Reports Project |
RCV000114009 | SCV000189319 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2011-03-14 | no assertion criteria provided | clinical testing | |
Department of Pathology and Laboratory Medicine, |
RCV001281077 | SCV000592234 | benign | Malignant tumor of breast | no assertion criteria provided | clinical testing | The p.Ala2951Thr variant has been reported in our laboratory as well as in the literature in 36/5864 (0.006 frequency) proband chromosomes and in 1/1018 control chromosomes (0.001 frequency) (Bergthorsson_2001_11389159, Borg_2010_20104584, Saxena_2006_17018160, Lin_2003_12815053, Spitzer_2000_10699917, Serova-Sinilnikova_1997_9150172, Weber_2006_16685647, Wagner_1999_9971877, Waddell_2008_18497862). It is listed in dbSNP database (ID#:rs11571769) but no frequency information was provided, and so the prevalence of this variant in the general population is not known. The p.Ala2951 residue is conserved across vertebrate species, and computational analyses (PolyPhen2, SIFT, AlignGVGD) suggest that the p.Ala2951Thr variant may impact the protein. However, this information is not predictive enough to assume pathogenicity. In one study, this variant did not co-segregate with cancer in three families, and its frequency in 4680 clinical samples was similar to that of the control population (Deffenbaugh_2002_12215251). Notably, this variant has been identified in the UMD database in a total of 15 individuals who had a second pathogenic variant (9 with BRCA2 mutations and 6 with BRCA1) and associated with a breast or ovarian cancer phenotype, increasing the likelihood that the p.Ala2951Thr variant does not have clinical significance. In addition, Myriad calls this variant as a polymorphism. In summary, based on the above information this variant is classified as benign. | |
Diagnostic Laboratory, |
RCV000114009 | SCV000733327 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | no assertion criteria provided | clinical testing | ||
Mayo Clinic Laboratories, |
RCV000034468 | SCV000778721 | likely benign | not provided | 2017-03-30 | no assertion criteria provided | clinical testing | |
True Health Diagnostics | RCV000128883 | SCV000787957 | benign | Hereditary cancer-predisposing syndrome | 2017-09-13 | no assertion criteria provided | clinical testing | |
Center of Medical Genetics and Primary Health Care | RCV001281077 | SCV001451692 | benign | Malignant tumor of breast | no assertion criteria provided | clinical testing | ||
Laboratory of Diagnostic Genome Analysis, |
RCV000120367 | SCV001799522 | benign | not specified | no assertion criteria provided | clinical testing | ||
Clinical Genetics Laboratory, |
RCV000120367 | SCV001906216 | benign | not specified | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000120367 | SCV001952725 | benign | not specified | no assertion criteria provided | clinical testing |